Company Highlights - Hanyu Pharmaceutical expects a net profit of 142 million to 162 million yuan for the first half of 2025, benefiting from increased global market demand and successful product approvals [1] - Taotao Automotive anticipates a net profit growth of 70% to 98% year-on-year for the first half of 2025, driven by enhanced brand influence and improved operational efficiency [2] - Xiaogoods City projects a net profit increase of 13% to 17% for the first half of 2025, attributed to growth in main business revenue and trade fulfillment services [2] - Hongxin Electronics signed contracts totaling 373 million yuan for computing power services through its subsidiaries [3] - Alloy Investment's controlling shareholder will change to Jiuzhou Hengchang, leading to the resumption of trading [3] - Hangzhou High-tech is planning a change in control, with a suspension of trading expected for no more than two trading days [4] - Junpu Intelligent signed a sales framework contract for humanoid robots worth 28.25 million yuan [7] - Lens Technology plans to issue 262 million H-shares globally, with an initial price range set between 17.38 and 18.18 HKD [8] - Saintno Biopharmaceuticals received a drug registration certificate for its product, further enhancing its market competitiveness [12] Investment & Contracts - Shenzhen Energy plans to invest 6.332 billion yuan in upgrading the Mawan Power Plant, aligning with national energy policies [17] - China Railway Construction won a contract worth 3.781 billion yuan for the China-Kyrgyzstan-Uzbekistan railway project [27] - China Railway secured contracts totaling approximately 5.343 billion yuan for the same railway project [28] - Zhongtian Technology's subsidiary won multiple marine energy project contracts totaling about 1.722 billion yuan [29] - Lande Group intends to acquire a 20.1667% stake in Jujia Technology for up to 121 million yuan, enhancing its capabilities in high-performance materials [21][22] Financing & Capital Increase - Yiwei Lithium Energy submitted an application for H-share issuance and listing in Hong Kong [30] - Jiadou Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [30] - Helin Micro-Nano is preparing to issue H-shares for listing in Hong Kong [30] Other Developments - Renfu Pharmaceutical received approval for its midazolam injection in France, with expected annual sales of approximately 33 million USD [31] - Kanghong Pharmaceutical obtained a drug registration certificate for its eye drop product, enhancing its product pipeline in the ophthalmology sector [32]

人福医药（600079）公告，近日控股子公司宜昌人福药业收到法国国家药品和健康产品安全局核准签发 的咪达唑仑注射液上市许可批准信。咪达唑仑注射液被批准的适应症包括清醒镇静、成人麻醉诱导前的 术前用药、儿童麻醉诱导前的术前用药以及重症监护病房中的镇静。宜昌人福于2023年12月提交上市许 可申请并获得受理，现获得上市批准，有效期五年。本项目累计研发投入约为800万元人民币。根据 IQVIA数据统计，2024年咪达唑仑注射液在法国市场的年销售额约为3300万美元。 ...

证券代码：002262 证券简称：恩华药业 江苏恩华药业股份有限公司投资者关系活动记录表 编号：2025-002 | 投资者关系活动 | √特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 √其他 参会股东调研 | | 参与单位名称及 | 国盛证券：胡偌碧；国金证券：刘创；平安证券：韩盟盟；西部证券自营： 李远剑、周密；大成基金：阳洪宇；中信证券：朱家成；易米基金：刘家 | | 人员姓名 | 曦；永赢基金：张晓榕；成都五福源投资管理有限公司：石志伟；林刚、 | | | 杜雄、于满意、王志祥、周长萍、聂凤忠、张安忠、王聪、武文俊、宗宗、 | | | 蒋允刚、杜群飞。 | | 时间 | 2025 年 4 月 25 日上午 10:10-11：10 | | | 徐州市经济技术开发区龙湖西路31号恩华科技大厦3楼301会议室。 | | 地点 | | | 上市公司接待人 | 董事长孙彭生、董事会秘书段保州、财务负责人李岗生、证券事务代表吴 | | 员姓名 | 继业。 | | | 就公司 2024 年度报告及公司 ...